Metaclipse participates in Georgia BIO Innovation Summit in Atlanta, Georgia on October 8, 2019.
Metaclipse completes an independent GLP-compliant toxicology/safety study performed by IIT Research Institute in Chicago, Illinois in August. The study was conducted in mice on vaccine alone and in combination with checkpoint inhibitors. No adverse related events are detected other than injection site cell infiltration.
Metaclipse Therapeutics receives SBIR Contract Phase II award for influenza vaccine development for the elderly. This product development award from the NIAID/NIH in September for $1.95M supports cGMP vaccine production efforts, further preclinical studies to assess immune response and viral challenge, as well as vaccine safety studies.
Metaclipse Therapeutics participated in the Pharmaceutical & BioScience Society Workshop on CMC Development for Biologics in Foster City, California on May 6.
Metaclipse Therapeutics obtains exclusive worldwide rites to the technology from Emory University in March.
Metaclipse Therapeutics receives SBIR Diversity Supplement award from the NCI/NIH in January for $98K. This award supports career development of under-represented scientists from minority backgrounds as well as additional process development studies.
Metaclipse Therapeutics attends NIDA/NIH sponsored “Vaccines for the Treatment of Opioid Abuse Disorder” conference in Bethesda, Maryland on October 23-24.
Metaclipse presents at WSGR Healthcare Innovations Investment Forum in Austin, Texas on December 6-8.
Metaclipse Therapeutics receives SBIR Direct Phase II award from the NCI/NIH in September 2017 for $1.86M. This product development award supports dose finding, safety studies, and cGMP-compliant process development activities.
Metaclipse Therapeutics receives SBIR Contract Phase I award for influenza vaccine development for the elderly. This award from the NIAID/NIH in August 2017 for $230K supports preclinical studies to assess immune response and viral challenge
Metaclipse Therapeutics conducts a Pre-IND meeting with the FDA in March to discuss CMC and safety study design.
Metaclipse Therapeutics participates in BIO International Convention, San Francisco, California on June 6-9, 2016.
Metaclipse Therapeutics attends the JP Morgan Investor Conference in San Francisco, California on January 11-15, 2016.
Metaclipse Therapeutics is accepted into the JLABS program in Houston, Texas in Q4 2015. JLABS is an incubator program operated by Johnson and Johnson.
Metaclipse Therapeutics presents a poster at the CPRIT (Cancer Prevention and Research Institute of Texas) Convention in Austin, Texas on November 10, 2015.
Metaclipse Therapeutics presents at the Georgia Bio Innovation Summit in Atlanta, Georgia on November 2, 2015.
Metaclipse Therapeutics presents to the Bio/Med Investor Network in Q4 2015 to raise an angel round of investment
Metaclipse Therapeutics receives a 5-year R01 Academia/Industry partnership award in 2015 for $2.5M. This proposal investigates Metaclipse’s MembrexTM immunotherapy in combination with immune checkpoint blockade inhibitors in newly available humanized mouse models. Funding commenced in April 2016.
Metaclipse Therapeutics receives funding from the Georgia Research Alliance for product development in 2015.
Metaclipse Therapeutics receives a grant from the Coulter Foundation in 2015.
Metaclipse Therapeutics presents at the 6th Global Atlanta Forum organized by the Georgia Indo-American Chamber of Commerce (GIACC)
Metaclipse Therapeutics participates in BIO International Convention, San Diego, California on June 23-26, 2014.
Metaclipse Therapeutics is selected for the NIH Niche Assessment Program. The National Institute of Health’s SBIR/STTR Niche Assessment Program is a nationwide program funded by NIH to assess the technology and market potential. (February 2014)
Metaclipse Therapeutics presents at the First USA-India Vaccine Forum organized by USA-India Business Summit in 2014.
Metaclipse Therapeutics receives SBIR Phase I award from NCI/NIH in August 2013 for $150K. Metaclipse Therapeutics received SBIR Phase I funding in August 2013 to develop the personalized immunotherapy for triple-negative breast cancer.
Metaclipse Therapeutics presents at the 11th Annual Georgia Life Sciences Summit, the Southeast region’s largest bioscience conference, on October 3, 2012, at the Georgia International Convention Center in Atlanta, Georgia.